PKN1 · Variant type: fusion · Fusion partner: TECR (Tex1Pex10)
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 84.7% | 15.3% | 82.96 |
| 2 | Baricitinib | 80.6% | 19.4% | 97.99 |
| 3 | Tofacitinib | 75.0% | 25.0% | 99.25 |
| 4 | Repotrectinib | 57.4% | 42.6% | 84.21 |
| 5 | Capivasertib | 55.4% | 44.6% | 96.48 |
| 6 | Fedratinib | 51.4% | 48.6% | 96.21 |
| 7 | Darovasertib | 48.2% | 51.8% | 96.99 |
| 8 | Upadacitinib | 43.0% | 57.0% | 97.98 |
| 9 | Selpercatinib | 41.3% | 58.7% | 96.72 |
| 10 | Deucravacitinib | 32.9% | 67.1% | 98.99 |
| 11 | Erdafitinib | 32.2% | 67.8% | 95.71 |
| 12 | Pacritinib | 30.2% | 69.8% | 88.64 |
| 13 | Abemaciclib | 25.8% | 74.3% | 91.48 |
| 14 | Defactinib | 25.3% | 74.7% | 92.68 |
| 15 | Tepotinib | 22.1% | 77.9% | 99.75 |
| 16 | Entrectinib | 21.0% | 79.0% | 93.69 |
| 17 | Ruxolitinib | 20.3% | 79.7% | 98.25 |
| 18 | Abrocitinib | 19.1% | 80.9% | 99.50 |
| 19 | Pexidartinib | 19.1% | 80.9% | 99.49 |
| 20 | Mitapivat | 17.5% | 82.5% | 100.00 |
| 21 | Rabusertib | 16.6% | 83.4% | 98.74 |
| 22 | Asciminib | 15.7% | 84.3% | 100.00 |
| 23 | Mobocertinib | 15.0% | 85.0% | 97.22 |
| 24 | Gilteritinib | 14.5% | 85.5% | 88.97 |
| 25 | Lazertinib | 13.0% | 87.0% | 97.47 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 84.7% | — | — |
| Baricitinib | 80.6% | — | — |
| Tofacitinib | 75.0% | — | — |
| Repotrectinib | 57.4% | — | — |
| Capivasertib | 55.4% | — | — |
| Fedratinib | 51.4% | — | — |
| Darovasertib | 48.2% | — | — |
| Upadacitinib | 43.0% | — | — |
| Selpercatinib | 41.3% | — | — |
| Deucravacitinib | 32.9% | — | — |
| Erdafitinib | 32.2% | — | — |
| Pacritinib | 30.2% | — | — |
| Abemaciclib | 25.8% | — | — |
| Defactinib | 25.3% | — | — |
| Tepotinib | 22.1% | — | — |
| Entrectinib | 21.0% | — | — |
| Ruxolitinib | 20.3% | — | — |
| Abrocitinib | 19.1% | — | — |
| Pexidartinib | 19.1% | — | — |
| Mitapivat | 17.5% | — | — |
| Rabusertib | 16.6% | — | — |
| Asciminib | 15.7% | — | — |
| Mobocertinib | 15.0% | — | — |
| Gilteritinib | 14.5% | — | — |
| Lazertinib | 13.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.0ms